Dermatomyositis causes muscle weakness and a distinctive skin rash, often appearing on the face, knuckles, and upper body. It's rare, affecting roughly 10 people per million annually, and treatment has long relied on corticosteroids and immunosuppressants borrowed from other autoimmune diseases. Researchers are now testing targeted therapies designed specifically for the immune pathways active in dermatomyositis.
What's actually going on in research
Trials are testing JAK inhibitors like tofacitinib and ruxolitinib for skin and muscle symptoms, B-cell depleting drugs including rituximab, and intravenous immunoglobulin (IVIG) to reduce dependence on steroids. Studies are also examining biomarkers that distinguish dermatomyositis subtypes, some linked to cancer and others to lung disease, which may guide more precise treatment.
JAK inhibitors
These pills block enzymes involved in inflammation signaling and have shown promise for both the rash and muscle weakness. Early results suggest they may work faster than traditional treatments.
Rituximab and B-cell targets
This infused antibody depletes immune cells called B-cells and is being tested as a steroid-sparing option. Some dermatomyositis patients already use it off-label with benefit.
Subtype-specific treatment
Researchers are identifying antibodies that define dermatomyositis subtypes, each with different risks for cancer or lung involvement. Trials are beginning to test whether treatments can be matched to subtype.
What to know before you search
Eligibility often depends on disease severity, antibody subtype, presence of lung involvement, and whether prior treatments like steroids or methotrexate have been tried.
What types of trials are currently open
- JAK inhibitor trials — Testing pills like tofacitinib and ruxolitinib to see if they improve skin rash and muscle strength while allowing lower steroid doses.
- B-cell depletion trials — Studies of rituximab and similar drugs that target B-cells, aiming to control inflammation with fewer side effects than high-dose steroids.
- IVIG trials — Testing intravenous immunoglobulin, a pooled antibody treatment, as a way to reduce disease activity and steroid dependence.
- Biomarker studies — Observational research tracking antibodies and other blood markers to predict disease course and treatment response.
- Lung disease trials — Testing treatments specifically for interstitial lung disease, a serious complication in some dermatomyositis patients.
Recently added Dermatomyositis trials
Take an experimental immune therapy for autoimmune disease
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.
Receive an infusion of engineered immune cells for muscle inflammation
This single-arm, open-label, phase I trial evaluates the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with refractory Idiopathic inflammatory myopathy (IIM).
Find Dermatomyositis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.